{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:46:50Z","timestamp":1783486010887,"version":"3.55.0"},"reference-count":45,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp &amp; Dohme (MSD)","award":["10020230"],"award-info":[{"award-number":["10020230"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Ceftolozane\/tazobactam (C\/T) is a combination of an antipseudomonal oxyiminoaminothiazolyl cephalosporin with potent in vitro activity against Pseudomonas aeruginosa and tazobactam, a known \u03b2-lactamase inhibitor. The aim of this study was to evaluate the activity of C\/T against clinical isolates of P. aeruginosa and Enterobacterales collected from five Latin American countries between 2016 and 2017, before its clinical use in Latin America, and to compare it with the activity of other available broad-spectrum antimicrobial agents. Methods: a total of 2760 clinical isolates (508 P. aeruginosa and 2252 Enterobacterales) were consecutively collected from 20 hospitals and susceptibility to C\/T and comparator agents was tested and interpreted following the current guidelines. Results: according to the CLSI breakpoints, 68.1% (346\/508) of P. aeruginosa and 83.9% (1889\/2252) of Enterobacterales isolates were susceptible to C\/T. Overall, C\/T demonstrated higher in vitro activity than currently available cephalosporins, piperacillin\/tazobactam and carbapenems when tested against P. aeruginosa, and its performance in vitro was comparable to fosfomycin. When tested against Enterobacterales, it showed higher activity than cephalosporins and piperacillin\/tazobactam, and similar activity to ertapenem. Conclusions: these results show that C\/T is an active \u03b2-lactam agent against clinical isolates of P. aeruginosa and Enterobacterales.<\/jats:p>","DOI":"10.3390\/antibiotics11081101","type":"journal-article","created":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T21:09:06Z","timestamp":1660511346000},"page":"1101","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparative In Vitro Activity of Ceftolozane\/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5569-6031","authenticated-orcid":false,"given":"Juan Carlos","family":"Garc\u00eda-Betancur","sequence":"first","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Resistencia Antimicrobiana y Epidemiolog\u00eda Hospitalaria, Universidad El Bosque, Bogot\u00e1 110121, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0361-7893","authenticated-orcid":false,"given":"Elsa","family":"De La Cadena","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Resistencia Antimicrobiana y Epidemiolog\u00eda Hospitalaria, Universidad El Bosque, Bogot\u00e1 110121, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1380-9824","authenticated-orcid":false,"given":"Mar\u00eda F.","family":"Mojica","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Resistencia Antimicrobiana y Epidemiolog\u00eda Hospitalaria, Universidad El Bosque, Bogot\u00e1 110121, Colombia"},{"name":"Department of Molecular Biology and Microbiology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106-7164, USA"},{"name":"Veterans Affairs Medical Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Case Western Reserve University-Cleveland, Cleveland, OH 44106-7164, USA"},{"name":"Research Service, VA Northeast Ohio Healthcare System, Cleveland, OH 44106-7164, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristhian","family":"Hern\u00e1ndez-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Resistencia Antimicrobiana y Epidemiolog\u00eda Hospitalaria, Universidad El Bosque, Bogot\u00e1 110121, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Correa","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Imbanaco, Cali 760031, Colombia"},{"name":"Facultad de Ciencias B\u00e1sicas, Universidad Santiago de Cali, Cali 760033, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela A.","family":"Radice","sequence":"additional","affiliation":[{"name":"Laboratorio de Resistencia Bacteriana, Facultad de Farmacia y Bioqu\u00edmica, IBaViM, Universidad de Buenos Aires, Buenos Aires 70512, Argentina"},{"name":"National Scientific and Technical Research Council (CONICET), Godoy Cruz, Buenos Aires 2290, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4460-9937","authenticated-orcid":false,"given":"Paulo","family":"Casta\u00f1eda-M\u00e9ndez","sequence":"additional","affiliation":[{"name":"Hospital M\u00e9dica Sur, Ciudad de M\u00e9xico 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego A.","family":"Jaime-Villalon","sequence":"additional","affiliation":[{"name":"Hospital M\u00e9dica Sur, Ciudad de M\u00e9xico 14050, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Gales","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo 04039-032, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7870-1056","authenticated-orcid":false,"given":"Jos\u00e9 M.","family":"Munita","sequence":"additional","affiliation":[{"name":"Millennium Initiative for Collaborative Research on Bacterial Resistance (MICROB-R), Santiago 7650568, Chile"},{"name":"Genomics and Resistant Microbes Group, Facultad de Medicina Cl\u00ednica Alemana, Universidad del Desarrollo, Santiago 8320000, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1898-9067","authenticated-orcid":false,"given":"Mar\u00eda Virginia","family":"Villegas","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Resistencia Antimicrobiana y Epidemiolog\u00eda Hospitalaria, Universidad El Bosque, Bogot\u00e1 110121, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,13]]},"reference":[{"key":"ref_1","first-page":"1803","article-title":"Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: Retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/CMR.00030-10","article-title":"Challenges of antibacterial discovery","volume":"24","author":"Silver","year":"2011","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3201\/eid2507.181938","article-title":"Carbapenem and cephalosporin resistance among enterobacteriaceae in healthcare- associated infections, california, usa1","volume":"25","author":"Rizzo","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.gendis.2019.04.001","article-title":"Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review","volume":"6","author":"Pachori","year":"2019","journal-title":"Genes Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1177\/1060028015593293","article-title":"Ceftolozane\/Tazobactam: A New Cephalosporin and \u03b2-Lactamase Inhibitor Combination","volume":"49","author":"Sucher","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1128\/AAC.01104-09","article-title":"Activity of a new cephalosporin, CXA-101 (FR264205), against \u03b2-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients","volume":"54","author":"Moya","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.bmc.2007.11.074","article-title":"Structural requirements for the stability of novel cephalosporins to AmpC \u03b2-lactamase based on 3D-structure","volume":"16","author":"Murano","year":"2008","journal-title":"Bioorganic Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1016\/j.bmcl.2008.07.085","article-title":"Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: Discovery of FR264205","volume":"18","author":"Toda","year":"2008","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Jean, S.S., Chang, Y.C., Lin, W.C., Lee, W.S., Hsueh, P.R., and Hsu, C.W. (2020). Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010275"},{"key":"ref_10","first-page":"215","article-title":"Ceftolozane\/tazobactam: A novel antipseudomonal cephalosporin and \u03b2-lactamase-inhibitor combination","volume":"6","author":"Hong","year":"2013","journal-title":"Infect. Drug Resist."},{"key":"ref_11","first-page":"787","article-title":"Critical evaluation of ceftolozane\u2013tazobactam for complicated urinary tract and intra-abdominal infections","volume":"12","author":"Giancola","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jgar.2019.10.009","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against contemporary (2015\u20132017) Pseudomonas aeruginosa isolates from a global surveillance programme","volume":"21","author":"Shortridge","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/Avibactam and Ceftolozane\/Tazobactam: Second-generation \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combinations","volume":"63","author":"Bonomo","year":"2016","journal-title":"Clin Infect Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","article-title":"New agents for the treatment of infections with Gram-negative bacteria: Restoring the miracle or false dawn?","volume":"23","author":"Wright","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e01026-20","DOI":"10.1128\/mSphere.01026-20","article-title":"Ceftolozane\/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa","volume":"6","author":"Teo","year":"2021","journal-title":"mSphere"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12)","volume":"69","author":"Sader","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1128\/AAC.01404-13","article-title":"In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012","volume":"57","author":"Walkty","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ijantimicag.2014.01.032","article-title":"Ceftolozane\/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)","volume":"43","author":"Farrell","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bjid.2017.06.008","article-title":"Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: Report from an antimicrobial surveillance program (2013\u20132015)","volume":"21","author":"Pfaller","year":"2017","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14787210.2020.1813023","article-title":"Update on the epidemiology of carbapenemases in Latin America and the Caribbean","volume":"19","author":"Appel","year":"2021","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"ref_22","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2022, March 13). Breakpoint Tables for Interpretation of MICs and Zone Diameters-EUCAST. Available online: http:\/\/www.eucast.org."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.eimc.2020.01.017","article-title":"Characterization of AmpC \u03b2-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane\/tazobactam during therapy","volume":"38","author":"Mulet","year":"2020","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e01117-20","DOI":"10.1128\/AAC.01117-20","article-title":"Mechanisms of resistance to ceftolozane\/tazobactam in pseudomonas aeruginosa: Results of the GERPA multicenter study","volume":"65","author":"Fournier","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e01970-17","DOI":"10.1128\/AAC.01970-17","article-title":"Activity of Ceftolozane-Tazobactam against Carbapenem- Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms","volume":"62","author":"Wi","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jgar.2020.04.017","article-title":"Ceftolozane-tazobactam and ceftazidime-avibactam activity against \u03b2-lactam-resistant Pseudomonas aeruginosa and extended-spectrum \u03b2-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres","volume":"22","author":"Hirsch","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_27","first-page":"10","article-title":"Use of fosfomycin combination therapy to treat multidrug-resistant urinary tract infection among paediatric surgical patients\u2013a tertiary care centre experience","volume":"2","author":"Shiju","year":"2020","journal-title":"Access Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"ofab320","DOI":"10.1093\/ofid\/ofab320","article-title":"Ceftolozane\/Tazobactam and Imipenem\/Relebactam Cross-Susceptibility among Clinical Isolates of Pseudomonas aeruginosa from Patients with Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017\u20132019","volume":"8","author":"Lob","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_29","first-page":"519","article-title":"Resistencia a los antibacterianos en Am\u00e9rica Latina: Consecuencias para la infectolog\u00eda","volume":"30","author":"Casellas","year":"2011","journal-title":"Rev. Panam. Salud Publica\/Pan Am. J. Public Heal."},{"key":"ref_30","first-page":"1","article-title":"Antimicrobial Resistance in Water in Latin America and the Caribbean: Available Research and Gaps","volume":"7","author":"Rivera","year":"2020","journal-title":"Front. Vet. Sci."},{"key":"ref_31","first-page":"82","article-title":"An analysis of the epidemic of klebsiella pneumoniae carbapenemase-producing k","volume":"217","author":"Rojas","year":"2018","journal-title":"pneumoniae: Convergence of two evolutionary mechanisms creates the \u2018perfect storm.\u2019 J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1128\/AAC.00695-12","article-title":"First report of a Pseudomonas aeruginosa isolate coharboring KPC and VIM carbapenemases","volume":"56","author":"Correa","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/14787210.2017.1268918","article-title":"The epidemiology of carbapenemases in Latin America and the Caribbean","volume":"15","author":"Reyes","year":"2017","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Losito, A.R., Raffaelli, F., del Giacomo, P., and Tumbarello, M. (2022). New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review. Antibiotics, 11.","DOI":"10.3390\/antibiotics11050579"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40121-022-00591-2","article-title":"Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa","volume":"11","author":"Coyne","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijantimicag.2017.09.016","article-title":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): Report from an Antimicrobial Surveillance Pr","volume":"51","author":"Pfaller","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and \u2018problem\u2019 Enterobacteriaceae, Pseudomonas Aeruginosa and non-fermenters from the British Isles","volume":"72","author":"Livermore","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12866-021-02135-z","article-title":"Activity of ceftolozane\/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections\u2013SMART United States 2018\u20132019","volume":"21","author":"Karlowsky","year":"2021","journal-title":"BMC Microbiol"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e02431-18","DOI":"10.1128\/AAC.02431-18","article-title":"Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa","volume":"63","author":"Yin","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jgar.2017.05.025","article-title":"Ceftolozane\u2013tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013\u20132015)","volume":"10","author":"Pfaller","year":"2017","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jac\/dkx009","article-title":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: Report from an antimicrobial surveillance programme (2012-15)","volume":"72","author":"Pfaller","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1128\/AAC.03681-14","article-title":"Mutation-Driven \u03b2-Lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible pseudomonas aeruginosa isolates from U.S. hospitals","volume":"58","author":"Castanheira","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e00875-17","DOI":"10.1128\/AAC.00875-17","article-title":"Multicenter Evaluation of CeftazidimeAvibactam and Ceftolozane-Tazobactam Inhibitory Activity against MeropenemNonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds","volume":"61","author":"Grupper","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","unstructured":"Weinstein, M.P., Kim, T.J., Lewis, J.S., Limbago, B., Bobenchik, A.M., Mathers, A.J., Campeau, S., Mazzulli, T., Cullen, S.K., and Satlin, M. (2020). Performance Standards for Antimicrobial Testing; CLSI Supplement M100, Clinical and Laboratory Standards Institute. [30th ed.]."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cmi.2019.03.017","article-title":"Evaluation of six commercial products for colistin susceptibility testing in Enterobacterales","volume":"25","author":"Pfennigwerth","year":"2019","journal-title":"Clin. Microbiol. Infect."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/8\/1101\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:08:17Z","timestamp":1760141297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/8\/1101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,13]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["antibiotics11081101"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11081101","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,13]]}}}